Scarlet Therapeutics wins $14m DARPA deal for smart red blood cells
Scarlet Therapeutics has secured an agreement with the US Defense Advanced Research Projects Agency worth up to $14 million to develop what the company calls smart red blood cells (SRBCs). The Bristol-based biotech will lead a multidisciplinary international consortium to engineer red blood cells capable of detecting physiological changes and adjusting their therapeutic activity in response.
The programme is exploratory and intended to assess feasibility; no clinical application is implied by the agreement. DARPA funding of this kind typically signals that a technology has cleared an internal bar for scientific novelty and potential dual-use value, and the award provides meaningful external validation for a platform that has so far attracted mainly academic and early-stage venture interest.
The consortium and its scope
Scarlet will coordinate partners spanning red blood cell biology, synthetic biology, computational design and automated cell manufacturing. Named members include the University of Bristol, where the company's foundational technology originated, Northwestern University in the United States, and cell-manufacturing specialist Unicorn Biotechnologies.
Professor Ash Toye, chief scientific officer and principal investigator of the consortium, said the programme will explore how engineered red blood cells can "sense and respond to changes in human physiology, while also advancing capabilities in protein retention, biological control, safety and automated manufacturing that could support a new generation of long-acting medicines."
The technical ambition is considerable. Current engineered-cell platforms, including most CAR-T and exosome-based approaches, deliver a fixed payload without feedback mechanisms. Building sensing and control logic into enucleated red blood cells, which lack the gene-expression machinery present in nucleated cells, represents a significant engineering challenge and is the core scientific question this programme aims to answer.
Market and competitive context
Scarlet sits within a small but growing field of red blood cell engineering companies seeking to turn RBCs into scalable, long-circulating drug-delivery vehicles. The appeal is practical: red cells are abundant, immunologically well-characterised, and circulate for roughly 120 days, making them attractive carriers for long-acting biologics. A number of academic groups and early-stage companies in the US and Europe are pursuing similar cell-loading strategies, though the addition of adaptive sensing circuitry is less common and would, if validated, represent a meaningful differentiator.
The company's broader platform targets two application areas: therapeutic RBCs for metabolic and other diseases, and universal off-the-shelf transfusion products. The RESTORE study, described as a first-in-human trial comparing lab-grown and donated red blood cells in healthy volunteers, provides a clinical thread linking the manufacturing platform to eventual translational ambitions, though it is separate from the DARPA programme.
DARPA agreements of this structure are typically milestone-based and carry no guarantee of full funding. The $14 million ceiling is contingent on technical progress, and the agency retains the right to terminate at defined review points. Nonetheless, the contract adds credibility at a stage when most red blood cell engineering companies are still presenting preclinical proof-of-concept data to investors.
Chief executive Alistair Irvine described the agreement as an endorsement of the technology and an opportunity to "address some of the most ambitious challenges in red blood cell engineering." The next milestones to watch will be consortium progress updates and any publication of feasibility data, which DARPA-funded programmes often feed into peer-reviewed literature before commercial development proceeds.